Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia

被引:85
作者
Brisco, MJ
Hughes, E
Neoh, SH
Sykes, PJ
Bradstock, K
Enno, A
Szer, J
McCaul, K
Morley, AA
机构
[1] FLINDERS UNIV S AUSTRALIA, MED CTR, DEPT HEMATOL, BEDFORD PK, SA 5042, AUSTRALIA
[2] WESTMEAD HOSP, DEPT HEMATOL, WESTMEAD, NSW, AUSTRALIA
[3] NEWCASTLE MATER MISERICORDIAE HOSP, DEPT HEMATOL, NEWCASTLE, NSW, AUSTRALIA
[4] ROYAL MELBOURNE HOSP, BONE MARROW TRANSPLANT SERV, MELBOURNE, VIC, AUSTRALIA
[5] S AUSTRALIAN HLTH COMMISS, ADELAIDE, SA, AUSTRALIA
关键词
D O I
10.1182/blood.V87.12.5251.bloodjournal87125251
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In children with acute lymphoblastic leukemia (ALL), the level of minimal residual disease (MRD) at the end of induction strongly predicts outcome, presumably because it measures both drug sensitivity and the number of leukemic cells requiring elimination, Children with high levels (>10(-3) leukemic cells per marrow cell) nearly always relapse, whereas those with low levels (<2 x 10(-5)) seldom do, However, the importance of MRD in adult ALL is unclear, We studied 27 patients aged 14 to 74 who were treated with a standard protocol and who attained morphological remission. MRD in the marrow at first remission was quantified by using the polymerase chain reaction (PCR), with the rearranged immunoglobulin heavy chain gene as a molecular marker. Levels of MRD varied from 3 x 10(-1) to <7 x 10(-7). The probability of long-term relapse-free survival was significantly related to the level of MRD and only one of nine patients with MRD >10(-3) did not relapse. For patients who did relapse, there was an inverse relationship between MRD level and the length of remission. Overall, MRD in adults in whom a translocation had not been identified was significantly higher than in comparably-treated children, suggesting that ALL in adults is more drug-resistant than in children. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:5251 / 5256
页数:6
相关论文
共 35 条
  • [1] BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772
  • [2] TREATMENT RESULTS IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA USING A UNIFORM CHEMOTHERAPY PROTOCOL
    BRADSTOCK, KF
    ENNO, A
    HUGHES, DO
    TSCHUCHNIGG, M
    KOUTTS, J
    ROBERTSON, TI
    LEE, CH
    SELDON, M
    VOWELS, M
    [J]. LEUKEMIA & LYMPHOMA, 1991, 4 (5-6) : 317 - 324
  • [3] DETECTION AND QUANTITATION OF NEOPLASTIC-CELLS IN ACUTE LYMPHOBLASTIC-LEUKEMIA, BY USE OF THE POLYMERASE CHAIN-REACTION
    BRISCO, MJ
    CONDON, J
    SYKES, PJ
    NEOH, SH
    MORLEY, AA
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (02) : 211 - 217
  • [4] DEVELOPMENT OF A HIGHLY SENSITIVE ASSAY, BASED ON THE POLYMERASE CHAIN-REACTION, FOR RARE LYMPHOCYTE-B CLONES IN A POLYCLONAL POPULATION
    BRISCO, MJ
    TAN, LW
    ORSBORN, AM
    MORLEY, AA
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1990, 75 (02) : 163 - 167
  • [5] OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION
    BRISCO, MJ
    CONDON, J
    HUGHES, E
    NEOH, SH
    SYKES, PJ
    SESHADRI, R
    TOOGOOD, I
    WATERS, K
    TAURO, G
    EKERT, H
    MORLEY, AA
    [J]. LANCET, 1994, 343 (8891) : 196 - 200
  • [6] CLARKSON B, 1985, SEMIN ONCOL, V12, P160
  • [7] MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA - PCR ANALYSIS OF IMMUNOGLOBULIN GENE REARRANGEMENTS
    COLESINCLAIR, M
    FORONI, L
    WRIGHT, F
    MEHTA, A
    PRENTICE, HG
    HOFFBRAND, AV
    [J]. LEUKEMIA & LYMPHOMA, 1993, 11 : 49 - 58
  • [8] CRONKITE EP, 1979, CLIN HAEMATOL, V8, P351
  • [9] DAURIOL L, 1989, LEUKEMIA, V3, P155
  • [10] HANSENHAGGE TE, 1989, BLOOD, V74, P1762